It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Syntaxin 6 is a SNARE family protein known to play an important role in intracellular trafficking. Here, we examined the tumorogenic role of syntaxin 6 in renal cell carcinoma (RCC). The Cancer Genome Atlas (TCGA) was queried for clinicopathologic data and syntaxin 6 expression. We found a significant difference in overall survival (OS) between groups, with high syntaxin 6 expression correlating with decreased survival. When stratifying the data based on histological subtype, the papillary RCC subtype exhibited a significant correlation between syntaxin 6 expression and survival. Using ROC curve, we calculated the area under the curve (AUC) to determine the ability of syntaxin 6 to predict 3-year overall survival. The AUC for syntaxin 6 was 0.73, significantly higher compared to 0.52 for T stage. Next, syntaxin 6 expression was evaluated in clear cell (786-O and Caki-1) and papillary (Caki-2 and ACHN) RCC cells. Syntaxin 6 expression was higher in Caki-1 and ACHN RCC cells. Silencing of syntaxin 6 in ACHN cells significantly decreased the cell viability (p < 0.001). Overall, syntaxin 6 could be a prognostic biomarker for patients with papillary RCC and syntaxin 6 inhibitors hold promise as a novel therapy against RCC.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Wake Forest School of Medicine, Department of Cancer Biology, Winston-Salem, USA (GRID:grid.241167.7) (ISNI:0000 0001 2185 3318)
2 LSU Health Sciences Center, Biostatistics Program, School of Public Health, New Orleans, USA (GRID:grid.279863.1) (ISNI:0000 0000 8954 1233)
3 University of Texas Health Science Center, School of Bioinformatics, Houston, USA (GRID:grid.267308.8) (ISNI:0000 0000 9206 2401)
4 Wake Forest School of Medicine, Department of Cancer Biology, Winston-Salem, USA (GRID:grid.241167.7) (ISNI:0000 0001 2185 3318); Wake Forest School of Medicine, Department of Urology, Winston-Salem, USA (GRID:grid.241167.7) (ISNI:0000 0001 2185 3318); Wake Forest Baptist Comprehensive Cancer Center, Wake Forest School of Medicine, Winston-Salem, USA (GRID:grid.241167.7) (ISNI:0000 0001 2185 3318)